US 11,692,042 B2
Anti-CD73 antibodies and methods of use thereof
Nicholas Stuart Wilson, San Carlos, CA (US); Jeremy Dale Waight, Everett, MA (US); Shawn Michael Jennings, Acton, MA (US); Olga Ignatovich, Cambridge (GB); Emmanuel Cyrille Pascal Briend, Cambridge (GB); Benjamin Maxime Morin, Somerville, MA (US); Oliver Schon, Cambridge (GB); and Spencer Campbell, Essex (GB)
Assigned to AGENUS INC., Lexington, MA (US)
Filed by Agenus Inc., Lexington, MA (US)
Filed on Mar. 8, 2019, as Appl. No. 16/296,532.
Claims priority of provisional application 62/640,850, filed on Mar. 9, 2018.
Prior Publication US 2019/0352418 A1, Nov. 21, 2019
Int. Cl. C07K 16/28 (2006.01); A61P 35/04 (2006.01); A61P 35/00 (2006.01); C07K 14/71 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 14/71 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01)] 22 Claims
 
1. An isolated antibody that specifically binds to human CD73, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the CDRH1, CDRH2, and CDRH3 amino acid sequences of the VH amino acid sequence of SEQ ID NO: 27, and the VL comprises the CDRL1, CDRL2, and CDRL3 amino acid sequences of the VL amino acid sequence of SEQ ID NO: 37.